ATI RN
Learning Cardiovascular Drugs Pharmacology Questions
Question 1 of 5
Class of I.V. IgG preparation is:
Correct Answer: D
Rationale: The correct answer is D: Immunoglobulins. Intravenous Immunoglobulin (IV IgG) preparations are derived from pooled human plasma containing a broad spectrum of antibodies. IV IgG is used for replacement therapy in immunodeficiency disorders and autoimmune diseases. Monoclonal antibodies (A) are specific antibodies produced by identical immune cells, not a class of IV IgG. Immunosuppressive agents (B) are drugs that suppress the immune system to prevent rejection in organ transplant patients. Interferons (C) are signaling proteins released by cells in response to pathogens, not a class of IV IgG. In summary, IV IgG preparations belong to the class of immunoglobulins, not monoclonal antibodies, immunosuppressive agents, or interferons.
Question 2 of 5
All of the following statements concerning the general principles of therapy with lipid-lowering drugs are true EXCEPT:
Correct Answer: B
Rationale: Answer B is correct because discontinuing a lipid-lowering diet solely based on the immediate reduction in plasma LDL cholesterol levels by 10% is not appropriate. The efficacy of a diet in managing lipid levels should be evaluated over a longer period, considering other factors like overall cardiovascular health and risk factors. Choosing to discontinue the diet based solely on the short-term reduction in LDL cholesterol levels can lead to overlooking other important aspects of cardiovascular health. Choices A, C, and D are incorrect: A: This statement is true because combining lipid-lowering drugs with an appropriate diet can enhance the overall effectiveness of therapy in managing lipid levels. C: This statement is also true as dietary interventions are usually recommended as the first-line approach before resorting to pharmacological therapy. D: This statement is true as certain combinations of lipid-lowering drugs can indeed work synergistically to achieve better outcomes in managing lipid levels.
Question 3 of 5
Route of administration of 25-hydroxyvitamin D3 (calcifediol) is:
Correct Answer: A
Rationale: The correct answer is A: Oral. Calcifediol is typically administered orally because it undergoes hepatic hydroxylation to form the active form of vitamin D, calcitriol. Subcutaneous (B) and intravenous (C) routes would bypass this necessary metabolic step. Intranasal (D) administration is not a common route for vitamin D supplementation. Therefore, oral administration ensures proper metabolism and bioavailability of calcifediol.
Question 4 of 5
Mineralocorticoid effects cause:
Correct Answer: B
Rationale: Mineralocorticoids, such as aldosterone, act on the kidneys to increase sodium retention and potassium excretion. This process helps regulate blood pressure and electrolyte balance. Increased catabolism (choice A) is not a direct effect of mineralocorticoids. Increased gluconeogenesis (choice C) is a function of glucocorticoids, not mineralocorticoids. Deposition of fat on shoulders, face, and abdomen (choice D) is associated with Cushing's syndrome due to excess cortisol, not mineralocorticoids. Therefore, the correct answer is B as it aligns with the known physiological actions of mineralocorticoids.
Question 5 of 5
Bactericidal effect is:
Correct Answer: C
Rationale: The correct answer is C: Destroying of bacterial cells. Bactericidal effect refers to the ability to kill bacteria. This is achieved by directly destroying the bacterial cells, leading to their death. Inhibition of bacterial cell division (A) and young bacterial cell growth (B) refer to bacteriostatic effects, which only stop bacterial growth but do not kill the bacteria. Formation of bacterial L-form (D) is a phenomenon where bacteria lose their cell wall and become resistant to antibiotics, but it does not directly relate to bactericidal action.